Home » Stocks » GNPX

Genprex, Inc. (GNPX)

Stock Price: $3.75 USD -0.08 (-2.09%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $3.85 +0.10 (2.67%) Jan 15, 7:57 PM
Market Cap 161.45M
Revenue (ttm) n/a
Net Income (ttm) -15.14M
Shares Out 39.06M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $3.75
Previous Close $3.83
Change ($) -0.08
Change (%) -2.09%
Day's Open 3.83
Day's Range 3.72 - 3.89
Day's Volume 929,999
52-Week Range 1.15 - 6.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 days ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET

Business Wire - 4 days ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing

Benzinga - 3 weeks ago

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited f...

Other stocks mentioned: CRDF, NVAX, TRIL, VXRT
Business Wire - 3 weeks ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces $12 million registered direct closing.

Business Wire - 3 weeks ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with...

Benzinga - 3 weeks ago

Genprex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. According to data from the World Health Organization, cancer is currently th...

Business Wire - 3 weeks ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes clinical-grade manufacturing of lead drug candidate, REQORSA

Zacks Investment Research - 1 month ago

Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Business Wire - 1 month ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes major manufacturing milestone with completion of technology transfer

Business Wire - 1 month ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex commences clinical trial site recruitment for Acclaim-1 clinical trial

Business Wire - 1 month ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's COO will present on December 1 at the Diamond Equity Research Emerging Growth Invitational

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Thomas Gallagher will participate as a panelist at the NYC-based Life Sciences Summit

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--George Gittes, MD Joins Genprex's Scientific Advisory Board

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces new clinical trial branding for upcoming trials in non-small cell lung cancer

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex receives conditional FDA acceptance of proprietary name Reqorsa(TM) for lead drug candidate

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints Eric Chapdelaine to VP of Manufacturing

Business Wire - 3 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Zooming with LD Micro virtual event

Business Wire - 3 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Cell and Gene Meeting on the Mesa

Business Wire - 4 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints new Vice President of Regulatory Affairs

Business Wire - 4 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Chairman and CEO will present on September 1, 2020 at the LD 500 Virtual Conference

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will Present at the Proactive Investor Forum on August 4 at 1:40 p.m. ET

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appears live on the Big Biz Show for a second time

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's collaborators at the University of Pittsburgh receive $2.5 million grant from the NIH to fund diabetes gene therapy study.

Benzinga - 8 months ago

Shares of the micro-cap gene therapy company Genprex Inc (NASDAQ: GNPX) were advancing strongly on above-average volume Tuesday.

Market Watch - 11 months ago

Shares of Genprex Inc. GNPX, +56.61% climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-tr...

Benzinga - 11 months ago

Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday.

24/7 Wall Street - 11 months ago

When companies see their shares rise by 100% or more in a single day, it’s usually because of a buyout or an extremely positive change in a company’s future prospects.

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Poten...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted f...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Of...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted ...

GlobeNewsWire - 1 year ago

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milesto...

GlobeNewsWire - 1 year ago

NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted f...

GuruFocus - 1 year ago

As our understanding of how cancer works evolves, so too are the methods that we are taking to treat the condition.

Other stocks mentioned: ATRA, BLUE, HEB, INCY

About GNPX

Genprex operates as a clinical-stage gene therapy company that develops therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes. It develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate REQORSA (quaratusugene ozeplasmid) for treatment for non-small cell lung cancer (NSCLC) has a multimodal mechanism o... [Read more...]

Industry
Biotechnology
IPO Date
Mar 29, 2018
CEO
J. Rodney Varner
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
GNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Genprex stock is "Strong Buy" and the 12-month stock price forecast is 6.67.

Price Target
$6.67
Analyst Consensus: Strong Buy